Levi & Korsinsky probes Procept BioRobotics over possible federal securities law violations

Reuters03-16

Levi & Korsinsky probes Procept BioRobotics over possible federal securities law violations

Levi & Korsinsky said it has opened an investigation into Procept BioRobotics over potential federal securities law violations. The firm cited comments by CFO Kevin Waters and CEO Larry Wood on a Q3 2025 earnings call that reaffirmed a USD 325.5 million revenue target and referenced maintaining handpiece average selling prices of about USD 3,200. It alleged the company had implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which it said reduced realized average selling prices. Levi & Korsinsky said Q4 2025 revenue was USD 17.4 million below guidance and FY 2026 revenue guidance of USD 410 million to USD 430 million was below analyst consensus. It also said the stock fell roughly 15% in a single session after the Q4 2025 results release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202603160027NEWSFILECNPR____20260316_288647_1) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619543573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 12:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619543573","market":"nz","top_or_hot":-1,"title":"Levi & Korsinsky probes Procept BioRobotics over possible federal securities law violations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Levi &amp; Korsinsky probes Procept BioRobotics over possible federal securities law violations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Levi &amp; Korsinsky said it has opened an investigation into Procept BioRobotics over potential federal securities law violations. The firm cited comments by CFO Kevin Waters and CEO Larry Wood on a Q3 2025 earnings call that reaffirmed a USD 325.5 million revenue target and referenced maintaining handpiece average selling prices of about USD 3,200. It alleged the company had implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which it said reduced realized average selling prices. Levi &amp; Korsinsky said Q4 2025 revenue was USD 17.4 million below guidance and FY 2026 revenue guidance of USD 410 million to USD 430 million was below analyst consensus. It also said the stock fell roughly 15% in a single session after the Q4 2025 results release.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202603160027NEWSFILECNPR____20260316_288647_1) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Levi & Korsinsky probes Procept BioRobotics over possible federal securities law violations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLevi & Korsinsky probes Procept BioRobotics over possible federal securities law violations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 12:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Levi &amp; Korsinsky probes Procept BioRobotics over possible federal securities law violations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Levi &amp; Korsinsky said it has opened an investigation into Procept BioRobotics over potential federal securities law violations. The firm cited comments by CFO Kevin Waters and CEO Larry Wood on a Q3 2025 earnings call that reaffirmed a USD 325.5 million revenue target and referenced maintaining handpiece average selling prices of about USD 3,200. It alleged the company had implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which it said reduced realized average selling prices. Levi &amp; Korsinsky said Q4 2025 revenue was USD 17.4 million below guidance and FY 2026 revenue guidance of USD 410 million to USD 430 million was below analyst consensus. It also said the stock fell roughly 15% in a single session after the Q4 2025 results release.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202603160027NEWSFILECNPR____20260316_288647_1) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6SZ5HX:1","article_id":"2619543573","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619543573","pubTimestamp":1773635336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Levi & Korsinsky said it has opened an investigation into Procept BioRobotics over potential federal securities law violations. The firm cited comments by CFO Kevin Waters and CEO Larry Wood on a Q3 2025 earnings call that reaffirmed a USD 325.5 million revenue target and referenced maintaining handpiece average selling prices of about USD 3,200. It alleged the company had implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which it said reduced realized average selling prices. Levi & Korsinsky said Q4 2025 revenue was USD 17.4 million below guidance and FY 2026 revenue guidance of USD 410 million to USD 430 million was below analyst consensus. It also said the stock fell roughly 15% in a single session after the Q4 2025 results release.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PRCT":"PROCEPT BioRobotics","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC"},"translate_title":"Levi&Korsinsky调查Procept BioRobotics可能违反联邦证券法的行为","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":0.9},"content_text":"Levi & Korsinsky probes Procept BioRobotics over possible federal securities law violations\n    \n\n        Levi & Korsinsky said it has opened an investigation into Procept BioRobotics over potential federal securities law violations. The firm cited comments by CFO Kevin Waters and CEO Larry Wood on a Q3 2025 earnings call that reaffirmed a USD 325.5 million revenue target and referenced maintaining handpiece average selling prices of about USD 3,200. It alleged the company had implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which it said reduced realized average selling prices. Levi & Korsinsky said Q4 2025 revenue was USD 17.4 million below guidance and FY 2026 revenue guidance of USD 410 million to USD 430 million was below analyst consensus. It also said the stock fell roughly 15% in a single session after the Q4 2025 results release.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 202603160027NEWSFILECNPR____20260316_288647_1) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619543573","isCrawlerRequest":true}